ABT Stock: Price, Earnings History and SEC Filings
Abbott Laboratories (ABT) last traded at $106.20, up 1.56% on the latest session and up 7.5% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $1.42 against an analyst estimate of $1.43, a miss of 0.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ABT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 21, 2026 | $1.42 | $1.43 | -0.70% |
| Jun 2026 | Jul 16, 2026 | $1.31 | $1.28 | +2.34% |
| Mar 2026 | Apr 16, 2026 | $1.15 | $1.14 | +0.88% |
| Dec 2025 | Jan 22, 2026 | $1.50 | $1.50 | +0.00% |
ABT beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How ABT reacts to earnings
Across its last 8 earnings releases, ABT moved 5.5% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-21 | Before open | -1.89% |
| 2026-07-16 | Before open | +10.71% |
| 2026-04-16 | Before open | -6.00% |
| 2026-01-22 | Before open | -10.04% |
| 2025-10-15 | Before open | -2.87% |
| 2025-07-17 | Before open | -8.52% |
| 2025-04-16 | Before open | +2.76% |
| 2025-01-22 | Before open | +0.85% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
Latest SEC filings for ABT
- 8-K · Oct 21, 2026Other events, Financial statements and exhibits
- 8-K · Oct 21, 2026Results of operations, Financial statements and exhibits
- 8-K · Aug 20, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Jul 28, 2026
- 8-K · Jul 16, 2026Results of operations, Financial statements and exhibits
- 10-Q · Apr 29, 2026
- 8-K · Apr 27, 2026Officer or director change, Bylaw change, Shareholder vote
- 8-K · Apr 17, 2026Other events, Financial statements and exhibits
- 8-K · Apr 16, 2026Results of operations, Financial statements and exhibits
- 8-K · Mar 23, 2026Other events, Financial statements and exhibits
Insider filing activity
ABT insiders filed 10 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ABT news
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy SystemNov 1, 2026 · finance.yahoo.com
- Dexcom Shakes Off Abbott-Tied Malaise As U.S. Wearables Market Takes OffOct 30, 2026 · finance.yahoo.com
- Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears?Oct 30, 2026 · finance.yahoo.com
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENOct 30, 2026 · finance.yahoo.com
- Capitol Hill's Top Trades: The Hottest Stocks Congress Is Trading Right NowOct 30, 2026 · kiplinger.com
- Point-of-Care International Normalized Ratio (INR) Testing Market Report 2026 | Secure 10.1% CAGR Gains as Abbott, Roche, Danaher and Siemens Healthineers Scale Home MonitoringOct 30, 2026 · finance.yahoo.com
- Perrigo exits infant-formula with sale to MeridianMadeOct 30, 2026 · just-food.com
- AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000Oct 29, 2026 · 247wallst.com
About Abbott Laboratories
Abbott Laboratories (ABT) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in IL. Its fiscal year ends in December.